Pure Science Limited
Unaudited Financial Statements
For the year ended 31 March 2025
Pages for Filing with Registrar
Company Registration No. 05396061 (England and Wales)
Pure Science Limited
Contents
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
Pure Science Limited
Balance Sheet
As at 31 March 2025
Page 1
2025
2024
as restated
Notes
£
£
£
£
Fixed assets
Tangible assets
4
8,760
21,079
Investments
5
2,523
2,523
11,283
23,602
Current assets
Debtors
7
450,879
535,973
Cash at bank and in hand
137,667
369,246
588,546
905,219
Creditors: amounts falling due within one year
8
(455,993)
(546,259)
Net current assets
132,553
358,960
Total assets less current liabilities
143,836
382,562
Creditors: amounts falling due after more than one year
9
(122,667)
(209,667)
Net assets
21,169
172,895
Capital and reserves
Called up share capital
10
1,230
1,230
Share premium account
190
190
Capital redemption reserve
50
50
Other reserves
320
320
Profit and loss reserves
19,379
171,105
Total equity
21,169
172,895
Pure Science Limited
Balance Sheet (Continued)
As at 31 March 2025
Page 2

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
B. M. Kaufhold
Director
Company Registration No. 05396061
Pure Science Limited
Notes to the Financial Statements
For the year ended 31 March 2025
Page 3
1
Accounting policies
Company information

Pure Science Limited is a private company limited by shares incorporated in England and Wales. The registered office is Charlotte Building, 17 Gresse Street, London, W1T 1QL.

1.1
Accounting convention

These financial statements have been prepared in accordance with Section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 9 of FRS 102 not to prepare consolidated accounts on the grounds that the group is considered small. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

These financial statements are prepared on the going concern basis. The directors have reasonable expectation that the company will continue in operational existence for the foreseeable future. The directors believe that the company will have sufficient funds to settle all of its liabilities as they fall due for at least 12 months from signing the accounts.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
1
Accounting policies
(Continued)
Page 4
1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website Domains
Over the useful economic life
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings and equipment
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The Company only has basic financial instruments measured at amortised cost, with no financial instruments classified as other or basic instruments measured at fair value.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
1
Accounting policies
(Continued)
Page 5

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
12
9
Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 6
3
Intangible fixed assets
Software
£
Cost
At 1 April 2024 and 31 March 2025
8,000
Amortisation and impairment
At 1 April 2024 and 31 March 2025
8,000
Carrying amount
At 31 March 2025
-
0
At 31 March 2024
-
0
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2024
42,275
Additions
2,579
Disposals
(26,572)
At 31 March 2025
18,282
Depreciation and impairment
At 1 April 2024
21,196
Depreciation charged in the year
3,945
Eliminated in respect of disposals
(15,619)
At 31 March 2025
9,522
Carrying amount
At 31 March 2025
8,760
At 31 March 2024
21,079
5
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
2,523
2,523
Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 7
6
Subsidiaries

Details of the company's subsidiaries at 31 March 2025 are as follows:

Name of undertaking
Registered
Nature of business
Class of
% Held
office key
shares held
Direct
Indirect
Pure Science Investments Limited
1
Investment company
Ordinary
100.00
0
Sense Loft Limited
1
Dormant
Ordinary
94.71
0
Sense Worldwide Inc.
2
Consulting services
Ordinary
100.00
0
Sense Worldwide Limited
1
Dormant
Ordinary
100.00
0
Registered Office address:
1
6th Floor, Charlotte Building, 17 Gresse Street, London, United Kingdom, W1T 1QL
2
2822 Washington Ave. Suit 805A, Albany, New York, 12210, USA
7
Debtors
2025
2024
as restated
Amounts falling due within one year:
£
£
Trade debtors
239,581
153,289
Corporation tax recoverable
10,143
-
0
Amounts owed by group undertakings
121,559
117,255
Other debtors
73,728
238,134
Prepayments and accrued income
5,868
27,295
450,879
535,973
8
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
87,000
87,000
Trade creditors
30,468
13,165
Corporation tax
86,130
70,597
Other taxation and social security
14,918
11,908
Other creditors
237,477
363,589
455,993
546,259

The company's assets are subject to a fixed and floating charge in favour of HSBC.

Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 8
9
Creditors: amounts falling due after more than one year
2025
2024
as restated
£
£
Bank loans and overdrafts
122,667
209,667
10
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 50p each
2,460
2,460
1,230
1,230

 

11
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
220,675
-
0
12
Related party transactions

At year end, Pure Science Limited was owed £34,325 (2024: £211,051) by Jeremy Brown, a director of the company. During the year the company paid Jeremy Brown dividends of £55,500 (2024: £149,051).

 

At the year end, Pure Science Limited owed £2,668 (2024: £4,541 owed by) to Bernard Kaufhold, a director of the company. During the year Bernard Kaufhold invoiced the company £42,000 (2024: £36,000) for services rendered. During the year the company paid Bernard Kaufhold dividends of £7,208 (2024: £19,357).

Pure Science Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 9
13
Prior period adjustment
Reconciliation of changes in equity
1 April
31 March
2023
2024
£
£
Adjustments to prior year
Updates to project based revenue recognition
-
(211,868)
Equity as previously reported
547,163
384,763
Equity as adjusted
547,163
172,895
Analysis of the effect upon equity
Profit and loss reserves
-
(211,868)
Reconciliation of changes in profit/(loss) for the previous financial period
2024
£
Adjustments to prior year
Updates to project based revenue recognition
(211,868)
Profit as previously reported
155,060
Loss as adjusted
(56,808)
14
Controlling party

The controlling parties are Jeremy Brown and Katrina Brown by virtue of their majority shareholding.

2025-03-312024-04-01falsefalsefalse23 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityJ. C. W. BrownB. M. Kaufhold053960612024-04-012025-03-31053960612025-03-31053960612024-03-3105396061core:OtherPropertyPlantEquipment2025-03-3105396061core:OtherPropertyPlantEquipment2024-03-3105396061core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3105396061core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3105396061core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3105396061core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3105396061core:ShareCapital2025-03-3105396061core:ShareCapital2024-03-3105396061core:SharePremium2025-03-3105396061core:SharePremium2024-03-3105396061core:CapitalRedemptionReserve2025-03-3105396061core:CapitalRedemptionReserve2024-03-3105396061core:OtherMiscellaneousReserve2025-03-3105396061core:OtherMiscellaneousReserve2024-03-3105396061core:RetainedEarningsAccumulatedLosses2025-03-3105396061core:RetainedEarningsAccumulatedLosses2024-03-3105396061core:ShareCapitalOrdinaryShareClass12025-03-3105396061core:ShareCapitalOrdinaryShareClass12024-03-3105396061bus:Director22024-04-012025-03-3105396061core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3105396061core:PlantMachinery2024-04-012025-03-31053960612023-04-012024-03-3105396061core:ComputerSoftware2024-03-3105396061core:ComputerSoftware2025-03-3105396061core:ComputerSoftware2024-03-3105396061core:OtherPropertyPlantEquipment2024-03-3105396061core:OtherPropertyPlantEquipment2024-04-012025-03-3105396061core:Subsidiary12024-04-012025-03-3105396061core:Subsidiary22024-04-012025-03-3105396061core:Subsidiary32024-04-012025-03-3105396061core:Subsidiary42024-04-012025-03-3105396061core:Subsidiary112024-04-012025-03-3105396061core:Subsidiary222024-04-012025-03-3105396061core:Subsidiary332024-04-012025-03-3105396061core:Subsidiary442024-04-012025-03-3105396061core:CurrentFinancialInstruments2025-03-3105396061core:CurrentFinancialInstruments2024-03-3105396061core:Non-currentFinancialInstruments2025-03-3105396061core:Non-currentFinancialInstruments2024-03-3105396061bus:OrdinaryShareClass12024-04-012025-03-3105396061bus:OrdinaryShareClass12025-03-3105396061bus:OrdinaryShareClass12024-03-3105396061bus:PrivateLimitedCompanyLtd2024-04-012025-03-3105396061bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3105396061bus:FRS1022024-04-012025-03-3105396061bus:AuditExemptWithAccountantsReport2024-04-012025-03-3105396061bus:Director12024-04-012025-03-3105396061bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP